Drug intelligence / Profile preview

Vanguard I-III

Development stage: Unknown
Lead developer: Zoetis
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

Vanguard I-III is a canine combination vaccine developed by Zoetis (formerly Pfizer Animal Health) designed to protect dogs against several highly contagious and potentially fatal viral diseases. It is a modified-live virus (MLV) vaccine containing attenuated strains of canine distemper virus (CDV), canine adenovirus type 2 (CAV2), and canine parainfluenza virus (CPIV). The CAV2 component provides cross-protection against canine adenovirus type 1 (CAV1), the causative agent of infectious canine hepatitis, as well as respiratory disease caused by CAV2. The vaccine is typically administered via subcutaneous or intramuscular injection to healthy dogs as part of a primary vaccination series or annual booster.

Brand names: Vanguard I-IIIVanguard
Other names: Vanguard 1-3Vanguard1-3Vanguard-1-3Canine Distemper-Adenovirus Type 2-Parainfluenza VaccineVanguard DA2P

Beyond the preview

Go deeper on Vanguard I-III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanguard I-III.

Explore the full profile